Georgene Schroeder

3.9k total citations
42 papers, 2.9k citations indexed

About

Georgene Schroeder is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Georgene Schroeder has authored 42 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 17 papers in Genetics and 12 papers in Oncology. Recurrent topics in Georgene Schroeder's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Acute Myeloid Leukemia Research (8 papers). Georgene Schroeder is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Acute Myeloid Leukemia Research (8 papers). Georgene Schroeder collaborates with scholars based in United States, United Kingdom and Canada. Georgene Schroeder's co-authors include Ruben A. Mesa, Ayalew Tefferi, Curtis A. Hanson, S. Vincent Rajkumar, Chin‐Yang Li, Peter M. Anderson, Keith M. Skubitz, Ryan A. Knudson, Rhett P. Ketterling and David M. Nagorney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Georgene Schroeder

42 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Georgene Schroeder United States 25 1.6k 1.4k 963 842 466 42 2.9k
Marina Marchetti Italy 34 1.6k 1.0× 1.5k 1.1× 1.2k 1.3× 448 0.5× 693 1.5× 100 3.6k
David Lawrence United States 29 1.5k 1.0× 764 0.6× 1.1k 1.1× 614 0.7× 72 0.2× 73 3.3k
Farrukh T. Awan United States 33 935 0.6× 2.0k 1.5× 748 0.8× 976 1.2× 198 0.4× 199 3.7k
Enrico Pogliani Italy 25 1.7k 1.1× 1.1k 0.8× 431 0.4× 515 0.6× 451 1.0× 75 2.9k
M Leporrier France 26 1.0k 0.6× 1.6k 1.2× 403 0.4× 606 0.7× 85 0.2× 107 3.5k
Robert S. Lavey United States 25 514 0.3× 774 0.6× 520 0.5× 724 0.9× 74 0.2× 52 2.5k
G Spencer-Green United States 19 1.1k 0.7× 509 0.4× 510 0.5× 375 0.4× 2.8k 5.9× 40 4.1k
Pirow Bekker United States 27 531 0.3× 544 0.4× 2.1k 2.2× 3.0k 3.5× 1.2k 2.6× 76 5.8k
Eva Lengfelder Germany 34 2.6k 1.7× 1.6k 1.2× 2.0k 2.1× 691 0.8× 507 1.1× 95 4.2k
Steve Dahlberg United States 22 647 0.4× 645 0.5× 747 0.8× 1.4k 1.7× 54 0.1× 40 3.4k

Countries citing papers authored by Georgene Schroeder

Since Specialization
Citations

This map shows the geographic impact of Georgene Schroeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georgene Schroeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georgene Schroeder more than expected).

Fields of papers citing papers by Georgene Schroeder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georgene Schroeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georgene Schroeder. The network helps show where Georgene Schroeder may publish in the future.

Co-authorship network of co-authors of Georgene Schroeder

This figure shows the co-authorship network connecting the top 25 collaborators of Georgene Schroeder. A scholar is included among the top collaborators of Georgene Schroeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georgene Schroeder. Georgene Schroeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2025). Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal of the European Academy of Dermatology and Venereology. 39(7). 1336–1351. 8 indexed citations
2.
Mesa, Ruben A., Ayalew Tefferi, Leigh A. Gray, et al.. (2003). In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia. 17(5). 849–855. 26 indexed citations
3.
Litzow, Mark R., Panagiotis Repoussis, Georgene Schroeder, et al.. (2002). Veno-occlusive Disease of the Liver after Blood and Marrow Transplantation: Analysis of Pre- and Post-transplant Risk Factors Associated with Severity and Results of Therapy with Tissue Plasminogen Activator. Leukemia & lymphoma. 43(11). 2099–2107. 13 indexed citations
4.
Tefferi, Ayalew, David P. Steensma, C. Christopher Hook, et al.. (2001). Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leukemia Research. 25(2). 183–185. 15 indexed citations
5.
Tefferi, Ayalew, Ruben A. Mesa, Georgene Schroeder, et al.. (2001). Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 113(3). 763–771. 149 indexed citations
6.
Mesa, Ruben A., Ayalew Tefferi, Michelle A. Elliott, et al.. (2001). A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 114(1). 111–113. 32 indexed citations
7.
Burch, Patrick A., Georgene Schroeder, Cristine Allmer, et al.. (2000). Phase II Evaluation of Continuous-Infusion 5-Fluorouracil, Leucovorin, Mitomycin-C, and Oral Dipyridamole in Advanced Measurable Pancreatic Cancer. American Journal of Clinical Oncology. 23(5). 534–537. 11 indexed citations
8.
Burch, Patrick A., Georgene Schroeder, Joseph Rubin, et al.. (1999). North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy. American Journal of Clinical Oncology. 22(5). 505–505. 3 indexed citations
9.
Tefferi, Ayalew, Ralph Levitt, Chin‐Yang Li, et al.. (1999). Phase II Study of 2-Chlorodeoxyadenosine in Combination With Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia. American Journal of Clinical Oncology. 22(5). 509–509. 11 indexed citations
10.
Martenson, James A., Thomas G. Shanahan, Michael J. O’Connell, et al.. (1999). Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy. Cancer. 86(4). 710–714. 5 indexed citations
11.
Letendre, Louis, Pierre Noël, William Lindsey White, et al.. (1999). Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leukemia Research. 23(9). 811–815. 4 indexed citations
12.
Anderson, Peter M., Georgene Schroeder, & Keith M. Skubitz. (1998). Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 83(7). 1433–1439. 171 indexed citations
13.
Lloyd, Ricardo V., Georgene Schroeder, James E. Krook, et al.. (1998). Prevalence and prognostic significance of neuroendocrine differentiation in colorectal carcinomas. Endocrine Pathology. 9(1). 35–42. 15 indexed citations
14.
Pitot, Henry C., Donald B. Wender, Matthew J. O’Connell, et al.. (1997). Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.. Journal of Clinical Oncology. 15(8). 2910–2919. 220 indexed citations
15.
Gelber, R.D., Aron Goldhirsch, Bernard F. Cole, et al.. (1996). A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer. JNCI Journal of the National Cancer Institute. 88(15). 1039–1045. 95 indexed citations
16.
Rubin, Joseph, James Gallagher, Georgene Schroeder, et al.. (1996). Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer. 78(9). 1888–1891. 42 indexed citations
17.
Witzig, Thomas E., Thomas M. Habermann, Paul J. Kurtin, et al.. (1995). S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer. 76(6). 1059–1064. 6 indexed citations
18.
Witzig, Thomas E., Louis Letendre, James B. Gerstner, et al.. (1995). Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial.. Journal of Clinical Oncology. 13(8). 2012–2015. 33 indexed citations
19.
Letendre, Louis, Ralph Levitt, Robert V. Pierre, et al.. (1995). Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid. American Journal of Hematology. 48(4). 233–236. 13 indexed citations
20.
Wieand, Sam, Georgene Schroeder, & Judith R. OʼFallon. (1994). Stopping when the experimental regimen does not appear to help. Statistics in Medicine. 13(13-14). 1453–1458. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Marchetti Breakdown of academic impact, for papers by David Lawrence Breakdown of academic impact, for papers by Farrukh T. Awan Breakdown of academic impact, for papers by Enrico Pogliani Breakdown of academic impact, for papers by M Leporrier Breakdown of academic impact, for papers by Robert S. Lavey Breakdown of academic impact, for papers by G Spencer-Green Breakdown of academic impact, for papers by Pirow Bekker Breakdown of academic impact, for papers by Eva Lengfelder Breakdown of academic impact, for papers by Steve Dahlberg
Rankless by CCL
2026